We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+22.36%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$386M
AUM Growth
+$36.6M
Cap. Flow
-$1.12M
Cap. Flow %
-0.29%
Top 10 Hldgs %
62.47%
Holding
49
New
11
Increased
11
Reduced
7
Closed
13
Avg Time Held
4.4 quarters
Top 10 Avg Time Held
4 quarters
Top 20 Avg Time Held
4.4 quarters

Top Buys

Rank Stock Value
1
PTE
PolarityTE, Inc. Common Stock
PTE
+$19M
2
AMAG
AMAG Pharmaceuticals
AMAG
+$9.29M
3
VRDN icon
Viridian Therapeutics
VRDN
+$8.46M
4
DNTH icon
Dianthus Therapeutics
DNTH
+$7.76M
5
XNCR icon
Xencor
XNCR
+$6.2M

Top Sells

Rank Stock Value
1
BPMC icon
Blueprint Medicines
BPMC
+$19.9M
2
AXGN icon
Axogen
AXGN
+$12.1M
3
ARDX icon
Ardelyx
ARDX
+$5.73M
4
ABLX
Ablynx NV
ABLX
+$4.91M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$4.06M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
AXGN icon
1
Axogen
AXGN
$2.18B
$72.4M 18.73%
1,440,000
-275,000
-16% -$12.1M
2015 Q1
13 quarters
LOXO
2
DELISTED
Loxo Oncology, Inc
LOXO
$30.4M 7.86%
175,000
-4,400
-2% -$661K
2016 Q3
7 quarters
CDXS icon
3
Codexis
CDXS
$154M
$25.2M 6.52%
1,750,000
+49,400
+3% +$644K
2014 Q1
17 quarters
KYNB icon
4
Kyntra Bio
KYNB
$24.8M
$22.5M 5.83%
14,400
– –
2014 Q4
14 quarters
BPMC icon
5
DELISTED
Blueprint Medicines
BPMC
$22.2M 5.75%
350,000
-250,000
-42% -$19.9M
2015 Q3
11 quarters
PTE
6
DELISTED
PolarityTE, Inc. Common Stock
PTE
$18.8M 4.87%
+32,000
New +$19M
2018 Q2
0 quarters
DCPH icon
7
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$16.5M 4.28%
420,000
+55,000
+15% +$1.62M
2018 Q1
1 quarter
VKTX icon
8
Viking Therapeutics
VKTX
$3.6B
$11.4M 2.95%
1,200,000
+99,200
+9% +$660K
2017 Q4
2 quarters
SBBP
9
DELISTED
Strongbridge Biopharma plc.
SBBP
$11M 2.84%
1,830,000
+240,000
+15% +$1.76M
2016 Q4
6 quarters
AGIO icon
10
Agios Pharmaceuticals
AGIO
$1.84B
$10.9M 2.83%
130,000
– –
2016 Q1
9 quarters
FENC icon
11
Fennec Pharmaceuticals
FENC
$376M
$9.87M 2.55%
945,000
+72,000
+8% +$854K
2017 Q4
2 quarters
CBAY icon
12
DELISTED
Cymabay Therapeutics
CBAY
$9.36M 2.42%
697,500
+32,500
+5% +$407K
2017 Q3
3 quarters
TGTX icon
13
TG Therapeutics
TGTX
$8.46B
$8.22M 2.13%
625,000
+350,800
+128% +$4.82M
2018 Q1
1 quarter
AMAG
14
DELISTED
AMAG Pharmaceuticals
AMAG
$8.19M 2.12%
+420,000
New +$9.29M
2018 Q2
0 quarters
VRDN icon
15
Viridian Therapeutics
VRDN
$2.07B
$7.69M 1.99%
+80,000
New +$8.46M
2018 Q2
0 quarters
OCUL icon
16
Ocular Therapeutix
OCUL
$1.66B
$7.5M 1.94%
1,111,000
– –
2018 Q1
1 quarter
DNTH icon
17
Dianthus Therapeutics
DNTH
$4.56B
$7.42M 1.92%
+34,375
New +$7.76M
2018 Q2
0 quarters
BOLD icon
18
DELISTED
Audentes Therapeutics, Inc
BOLD
$7.26M 1.88%
190,000
– –
2017 Q2
4 quarters
SGMO icon
19
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$7.17M 1.86%
505,000
-30,000
-6% -$498K
2016 Q4
6 quarters
XOMA icon
20
DELISTED
Xoma
XOMA
$6.68M 1.73%
320,200
– –
2017 Q1
5 quarters
XNCR icon
21
Xencor
XNCR
$1.86B
$6.66M 1.72%
+180,000
New +$6.2M
2018 Q2
0 quarters
CORI
22
DELISTED
Corium International, Inc.
CORI
$6.41M 1.66%
800,000
-265,000
-25% -$2.51M
2015 Q4
10 quarters
CDTX icon
23
DELISTED
Cidara Therapeutics
CDTX
$6.24M 1.62%
+60,000
New +$5.66M
2018 Q2
0 quarters
RARE icon
24
Ultragenyx Pharmaceutical
RARE
$1.51B
$6.15M 1.59%
80,000
– –
2017 Q4
2 quarters
PTCT icon
25
PTC Therapeutics
PTCT
$5.25B
$6.07M 1.57%
180,000
+35,000
+24% +$1.09M
2018 Q1
1 quarter
1
2

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2018 Portfolio in Review

As of Q2 2018, Opaleye Management held 49 positions worth $386M, up 10% from $350M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Opaleye Management's Q2 2018 filing shows 11 new, 11 increased, 7 reduced and 13 closed positions. Its largest new stake was PolarityTE, Inc. Common Stock: 32,000 shares worth $18.8M. The largest sale was Blueprint Medicines, an estimated $19.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 94% a quarter earlier.

  • Opaleye Management's largest Q2 2018 buy was PolarityTE, Inc. Common Stock: 32,000 shares worth $18.8M.
  • Opaleye Management added most to TG Therapeutics in Q2 2018, an estimated $4.82M increase.
  • Opaleye Management's biggest Q2 2018 reduction was Blueprint Medicines, cutting an estimated $19.9M.
  • Opaleye Management fully exited Ardelyx in Q2 2018, selling an estimated $5.73M.
  • Opaleye Management's ten largest holdings make up 62% of its $386M portfolio in Q2 2018.
  • Opaleye Management opened 11 new positions and closed 13 in Q2 2018.
  • Opaleye Management's portfolio value rose 10% quarter-over-quarter to $386M.

Based on Opaleye Management's 13F filing for Q2 2018, filed 14 Aug 2018.